Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Rapid Communication: Molecular assays as initial tests for the diagnosis of tuberculosis and rifampicin resistance

Report
Rapid Communication: Molecular assays as initial tests for the diagnosis of tuberculosis and rifampicin resistance

This material aims to inform national TB Programmes and other stakeholders about the key implications of the latest evidence on the use of specific molecular assays as initial diagnostic tests of pulmonary and extrapulmonary TB and RR-TB, in adults and children.

Author:

World Health Organization

Audiences:

International Agencies, Physicians

Topic:

Diagnosis, Extrapulmonary TB, TB

Country of Origin:

Switzerland

View Webpage

Related Materials

Report of Expert Consultations on Rapid Molecular Testing to Detect Drug-Resistant Tuberculosis in the United States

This report presents results from an expert panel convened by CDC to examine the current status of rapid drug-resistance (DR) testing in the United States; to research published evidence and current guidelines; and to provide guidance and make recommendations to CDC for developing a system to provide access to rapid drug-susceptibility testing to all TB control programs in the United States. The panel recommended that CDC establish regional laboratories to provide molecular drug-resistance testing services to state and local TB programs. A phased approach to developing and implementing the testing service was advised. The panel also strongly recommended that CDC immediately establish a service to provide molecular DR testing for TB suspects and patients at high risk of having MDR TB and those deemed high priority by the state or local TB program. The report discusses the background on tests for molecular detection of DR, general considerations and principles for a molecular DR testing service, possible scenarios and scope of testing for such a service, research needs, general recommendations, a communication plan for the report recommendations, and a list of panel members and CDC participants. The appendices include a molecular basis of DR and molecular DR tests, roles and responsibilities in a regional laboratory system for providing for molecular DR testing for TB, and a flow chart of steps in a molecular DR testing service.

Report

Rapid Communication: Key changes to the treatment of drug-resistant tuberculosis

This document informs national TB programs and stakeholders about the key implications for the treatment of drug-resistant tuberculosis. This resource is available before the release of the updated guidelines in order for planning at the country level. The guidelines are expected to be released in 2020.

Report

CDC’s Molecular Detection of Drug Resistance Service: Rapid Test Results for Real-Time Patient Care

The infographic provides information on the importance of CDC's Molecular Detection of Drug Resistance (MDDR) service, how drug resistance develops, and how CDC assists TB programs. The infographic also includes a case study.

Fact Sheet

Global resources for the prevention,
management, and elimination of TB.